JP2021501145A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501145A5 JP2021501145A5 JP2020523028A JP2020523028A JP2021501145A5 JP 2021501145 A5 JP2021501145 A5 JP 2021501145A5 JP 2020523028 A JP2020523028 A JP 2020523028A JP 2020523028 A JP2020523028 A JP 2020523028A JP 2021501145 A5 JP2021501145 A5 JP 2021501145A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pharmaceutical composition
- cancer
- heterocyclyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims description 92
- 125000000217 alkyl group Chemical group 0.000 claims description 74
- 229910052739 hydrogen Inorganic materials 0.000 claims description 57
- 239000001257 hydrogen Substances 0.000 claims description 57
- -1 isooxazolyl Chemical group 0.000 claims description 57
- 150000002431 hydrogen Chemical class 0.000 claims description 49
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 44
- 125000001424 substituent group Chemical group 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 35
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 201000011510 cancer Diseases 0.000 claims description 30
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 23
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 239000012664 BCL-2-inhibitor Substances 0.000 claims description 16
- 125000003386 piperidinyl group Chemical group 0.000 claims description 16
- 208000032839 leukemia Diseases 0.000 claims description 15
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 14
- 229910052760 oxygen Inorganic materials 0.000 claims description 14
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 14
- 229910052717 sulfur Inorganic materials 0.000 claims description 14
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 13
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 12
- 125000002757 morpholinyl group Chemical group 0.000 claims description 11
- 125000004193 piperazinyl group Chemical group 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 125000002252 acyl group Chemical group 0.000 claims description 10
- 125000003107 substituted aryl group Chemical group 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 9
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000002393 azetidinyl group Chemical group 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 125000002971 oxazolyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 208000009527 Refractory anemia Diseases 0.000 claims description 5
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims description 5
- 210000000481 breast Anatomy 0.000 claims description 5
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 5
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 5
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000001544 thienyl group Chemical group 0.000 claims description 5
- 125000001425 triazolyl group Chemical group 0.000 claims description 5
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 208000007054 Medullary Carcinoma Diseases 0.000 claims description 4
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 4
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 4
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims description 4
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 4
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 4
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 claims description 4
- 201000004931 neurofibromatosis Diseases 0.000 claims description 4
- 208000029974 neurofibrosarcoma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000037244 polycythemia vera Diseases 0.000 claims description 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- OFFUJIKWPPOPOZ-UHFFFAOYSA-N 2-(1,3-oxazol-4-yl)acetamide Chemical compound NC(=O)CC1=COC=N1 OFFUJIKWPPOPOZ-UHFFFAOYSA-N 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 3
- HIDYWAGOMSFXRB-UHFFFAOYSA-N 6-(6-aminopyridin-3-yl)-N-(2-morpholin-4-yl-[1,3]oxazolo[5,4-b]pyridin-5-yl)pyridine-2-carboxamide Chemical compound NC1=CC=C(C=N1)C1=NC(=CC=C1)C(=O)NC1=CC=C2C(=N1)OC(=N2)N2CCOCC2 HIDYWAGOMSFXRB-UHFFFAOYSA-N 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims description 2
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 claims description 2
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 claims description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010073365 Intraductal papillary mucinous carcinoma of pancreas Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 101150053046 MYD88 gene Proteins 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 claims description 2
- 201000004404 Neurofibroma Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010067517 Pancreatic neuroendocrine tumour Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038019 Rectal adenocarcinoma Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 2
- 201000009036 biliary tract cancer Diseases 0.000 claims description 2
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 2
- 201000000053 blastoma Diseases 0.000 claims description 2
- 201000008274 breast adenocarcinoma Diseases 0.000 claims description 2
- 201000006662 cervical adenocarcinoma Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 2
- 201000008184 embryoma Diseases 0.000 claims description 2
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000000564 macroglobulinemia Diseases 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000003097 mucus Anatomy 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 230000002611 ovarian Effects 0.000 claims description 2
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims description 2
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 201000004754 pancreatic intraductal papillary-mucinous neoplasm Diseases 0.000 claims description 2
- 208000021010 pancreatic neuroendocrine tumor Diseases 0.000 claims description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 claims description 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 2
- 201000001281 rectum adenocarcinoma Diseases 0.000 claims description 2
- 230000001568 sexual effect Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 230000007704 transition Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical group C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims description 2
- 229960001183 venetoclax Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 61
- 125000001475 halogen functional group Chemical group 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 3
- 125000004939 6-pyridyl group Chemical group N1=CC=CC=C1* 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical group CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 claims 1
- 206010038272 Refractory anaemia with ringed sideroblasts Diseases 0.000 claims 1
- 208000013685 acquired idiopathic sideroblastic anemia Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical group NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 108
- 125000005843 halogen group Chemical group 0.000 description 27
- 229910052736 halogen Inorganic materials 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 14
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 6
- 125000003710 aryl alkyl group Chemical group 0.000 description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 6
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 6
- 0 Cc1nc(nc(*)c(C)c2)c2[s]1 Chemical compound Cc1nc(nc(*)c(C)c2)c2[s]1 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 229940045793 B-cell lymphoma-2 inhibitor Drugs 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000001984 thiazolidinyl group Chemical group 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 1
- GTKVXHNHLXCCTB-UHFFFAOYSA-N [1-[1-(2-methoxyethyl)-5-[2-(2-methylpyridin-4-yl)-2H-1,3-oxazol-3-yl]indazol-6-yl]piperidin-4-yl]methanamine Chemical compound COCCn1ncc2cc(N3C=COC3c3ccnc(C)c3)c(cc12)N1CCC(CN)CC1 GTKVXHNHLXCCTB-UHFFFAOYSA-N 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 1
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023034551A JP7476380B2 (ja) | 2017-10-31 | 2023-03-07 | 血液学的障害を治療するための化合物および組成物 |
| JP2024066487A JP2024096919A (ja) | 2017-10-31 | 2024-04-17 | 血液学的障害を治療するための化合物および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579502P | 2017-10-31 | 2017-10-31 | |
| US62/579,502 | 2017-10-31 | ||
| PCT/US2018/058194 WO2019089580A1 (en) | 2017-10-31 | 2018-10-30 | Compounds and compositions for treating hematological disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034551A Division JP7476380B2 (ja) | 2017-10-31 | 2023-03-07 | 血液学的障害を治療するための化合物および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501145A JP2021501145A (ja) | 2021-01-14 |
| JP2021501145A5 true JP2021501145A5 (enExample) | 2021-12-09 |
| JP7241747B2 JP7241747B2 (ja) | 2023-03-17 |
Family
ID=66328095
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523028A Active JP7241747B2 (ja) | 2017-10-31 | 2018-10-30 | 血液学的障害を治療するための化合物および組成物 |
| JP2023034551A Active JP7476380B2 (ja) | 2017-10-31 | 2023-03-07 | 血液学的障害を治療するための化合物および組成物 |
| JP2024066487A Withdrawn JP2024096919A (ja) | 2017-10-31 | 2024-04-17 | 血液学的障害を治療するための化合物および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034551A Active JP7476380B2 (ja) | 2017-10-31 | 2023-03-07 | 血液学的障害を治療するための化合物および組成物 |
| JP2024066487A Withdrawn JP2024096919A (ja) | 2017-10-31 | 2024-04-17 | 血液学的障害を治療するための化合物および組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10758518B2 (enExample) |
| EP (2) | EP4410377A3 (enExample) |
| JP (3) | JP7241747B2 (enExample) |
| KR (2) | KR102697663B1 (enExample) |
| CN (2) | CN117064897A (enExample) |
| AU (3) | AU2018359248B2 (enExample) |
| BR (1) | BR112020008214A2 (enExample) |
| CA (1) | CA3079628A1 (enExample) |
| DK (1) | DK3704108T3 (enExample) |
| EA (1) | EA202090497A1 (enExample) |
| ES (1) | ES2979273T3 (enExample) |
| FI (1) | FI3704108T3 (enExample) |
| HR (1) | HRP20240700T1 (enExample) |
| HU (1) | HUE067356T2 (enExample) |
| IL (3) | IL274248B2 (enExample) |
| LT (1) | LT3704108T (enExample) |
| MX (2) | MX2020003666A (enExample) |
| MY (1) | MY203827A (enExample) |
| PH (1) | PH12020550457A1 (enExample) |
| PL (1) | PL3704108T3 (enExample) |
| PT (1) | PT3704108T (enExample) |
| RS (1) | RS65572B1 (enExample) |
| SG (1) | SG11202002386WA (enExample) |
| SI (1) | SI3704108T1 (enExample) |
| SM (1) | SMT202400216T1 (enExample) |
| WO (1) | WO2019089580A1 (enExample) |
| ZA (1) | ZA202500725B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311677B2 (en) | 2014-01-13 | 2025-06-01 | Aurigene Oncology Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| CN120267671A (zh) | 2017-03-31 | 2025-07-08 | 奥锐金肿瘤有限公司 | 用于治疗血液病的化合物和组合物 |
| EP4410377A3 (en) * | 2017-10-31 | 2024-11-13 | Curis, Inc. | Compounds and compositions for treating hematological disorders |
| JP7353474B2 (ja) * | 2019-09-24 | 2023-09-29 | 上海美悦生物科技発展有限公司 | Ｉｒａｋ阻害剤、その製造方法及び用途 |
| EP4132938A1 (en) | 2020-04-07 | 2023-02-15 | Bayer Aktiengesellschaft | Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances |
| AU2021321350A1 (en) * | 2020-08-03 | 2023-03-16 | Curis, Inc. | Compositions and methods for treating diseases and disorders |
| CA3199157A1 (en) * | 2020-11-18 | 2022-05-27 | Reinhard Von Roemeling | Methods of treating diseases and disorders |
| WO2022135338A1 (zh) * | 2020-12-25 | 2022-06-30 | 南京明德新药研发有限公司 | 酰胺噁唑类化合物 |
| CA3214747A1 (en) * | 2021-04-08 | 2022-10-13 | Reinhard Von Roemeling | Combination therapies for the treatment of cancer |
| CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
| TW202328150A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途 |
| TW202328151A (zh) | 2021-09-07 | 2023-07-16 | 德商拜耳廠股份有限公司 | 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途 |
| CN117177965B (zh) | 2021-12-23 | 2024-04-30 | 杭州多域生物技术有限公司 | 一种五元并六元化合物、制备方法、药物组合物和应用 |
| CA3251930A1 (en) * | 2022-05-11 | 2023-11-16 | Curis, Inc. | TREATMENT OF DISEASES AND DISORDERS WITH MIRACLES MODIFYING COMPOUNDS 4 |
| WO2025090844A1 (en) * | 2023-10-27 | 2025-05-01 | Curis, Inc. | Methods of treating cancer associated with reduced interleukin 1 beta expression |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| AU649421B2 (en) | 1990-05-18 | 1994-05-26 | Sanofi-Aventis Deutschland Gmbh | Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| DE69818675T2 (de) | 1997-07-29 | 2004-07-29 | Alcon Laboratories, Inc., Fort Worth | Galaktomannanpolymere und borat enthaltende augenarzneimittel |
| AU2483599A (en) | 1998-01-29 | 1999-08-16 | Sepracor, Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| DE10023486C1 (de) | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US20030134836A1 (en) | 2001-01-12 | 2003-07-17 | Amgen Inc. | Substituted arylamine derivatives and methods of use |
| EP1617840A4 (en) | 2003-05-01 | 2008-08-20 | Bristol Myers Squibb Co | PYRAZOLE AMID COMPOUNDS AS KINASE INHIBITORS |
| ATE556067T1 (de) | 2003-05-20 | 2012-05-15 | Ajinomoto Kk | Modulatoren des vanilloid rezeptors |
| US20050004133A1 (en) | 2003-06-05 | 2005-01-06 | Makings Lewis R. | Modulators of VR1 receptor |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| WO2005034870A2 (en) | 2003-10-07 | 2005-04-21 | Renovis, Inc. | Amide compounds and ion channel ligands and uses thereof |
| WO2005107460A1 (en) | 2004-04-22 | 2005-11-17 | Bayer Cropscience Lp | Method and composition for controlling weeds |
| US7906533B2 (en) | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1655297A1 (en) | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| JP2008519850A (ja) | 2004-11-10 | 2008-06-12 | シンタ ファーマシューティカルズ コーポレーション | Ｉｌ−１２調節化合物 |
| ATE446962T1 (de) | 2004-12-17 | 2009-11-15 | Lilly Co Eli | Thiazolopyridinon-derivate als mch- rezeptorantagonisten |
| JP4988591B2 (ja) | 2004-12-17 | 2012-08-01 | イーライ リリー アンド カンパニー | 新規なｍｃｈ受容体アンタゴニスト |
| EP1674467A1 (en) | 2004-12-22 | 2006-06-28 | 4Sc Ag | 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| WO2007058626A1 (en) | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| CN102633783A (zh) | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| GB0606429D0 (en) | 2006-03-30 | 2006-05-10 | Novartis Ag | Organic compounds |
| US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| US20080293785A1 (en) | 2006-04-11 | 2008-11-27 | Connolly Peter J | Substituted benzothiazole kinase inhibitors |
| CN101594909A (zh) | 2006-09-07 | 2009-12-02 | 比奥根艾迪克Ma公司 | 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂 |
| NZ575410A (en) | 2006-09-07 | 2012-03-30 | Biogen Idec Inc | 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives |
| US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| EP2121621B1 (en) | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
| JP4785881B2 (ja) | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| JP5364875B2 (ja) | 2007-07-16 | 2013-12-11 | アッヴィ・インコーポレイテッド | タンパク質キナーゼ阻害薬としてのインダゾール類、ベンゾイソオキサゾール類およびベンゾイソチアゾール類 |
| US8399448B2 (en) | 2007-08-08 | 2013-03-19 | Merck Serono Sa | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis |
| JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ，インコーポレーテッド | ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法 |
| EP2367598B1 (en) | 2008-11-19 | 2014-04-09 | Merck Sharp & Dohme Corp. | Inhibitors of diacylglycerol acyltransferase |
| WO2010071819A1 (en) | 2008-12-19 | 2010-06-24 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| CN102264701A (zh) | 2008-12-23 | 2011-11-30 | 霍夫曼-拉罗奇有限公司 | 作为p2x7调节剂的二氢吡啶酮脲 |
| ES2749504T3 (es) | 2009-10-13 | 2020-03-20 | Ligand Pharm Inc | Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos |
| US8822447B2 (en) | 2010-04-22 | 2014-09-02 | Janssen Pharmaceutica Nv | Indazole compounds useful as ketohexokinase inhibitors |
| US20130053382A1 (en) | 2010-04-30 | 2013-02-28 | Sunil Paliwal | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| JP5985473B2 (ja) | 2010-07-13 | 2016-09-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体 |
| RU2632900C2 (ru) | 2010-11-19 | 2017-10-11 | Лиганд Фармасьютикалс Инкорпорейтед | Гетероциклические амины и их применение |
| HUE029617T2 (en) | 2010-12-20 | 2017-03-28 | Merck Serono Sa | Indazolyl triazole derivatives as IRAK inhibitors |
| WO2012142125A2 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| KR20140077963A (ko) | 2011-10-20 | 2014-06-24 | 글락소스미스클라인 엘엘씨 | 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체 |
| GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| KR101385603B1 (ko) | 2012-05-17 | 2014-04-21 | 한국원자력의학원 | 벤조티아졸 유도체 및 암 치료를 위한 그의 용도 |
| WO2014003483A1 (en) | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
| EP2872144A4 (en) | 2012-07-11 | 2015-12-02 | Nimbus Iris Inc | IRAQ INHIBITOR AND USES THEREOF |
| EP2914592B1 (en) | 2012-11-03 | 2017-10-11 | Boehringer Ingelheim International GmbH | Inhibitors of cytomegalovirus |
| US9168257B2 (en) | 2013-05-22 | 2015-10-27 | Children's Hospital Medical Center | Combination therapy for MDS |
| TWI652014B (zh) | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| HK1231480A1 (zh) * | 2014-01-10 | 2017-12-22 | Aurigene Discovery Technologies Limited | 作为irak4抑制剂的吲唑化合物 |
| IL311677B2 (en) * | 2014-01-13 | 2025-06-01 | Aurigene Oncology Ltd | Bicyclic heterocyclyl derivatives as irak4 inhibitors |
| MX2016010056A (es) | 2014-02-06 | 2016-11-15 | Abbvie Inc | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. |
| CA2952188A1 (en) * | 2014-06-20 | 2015-12-23 | Aurigene Discovery Technologies Limited | Substituted indazole compounds as irak4 inhibitors |
| EP3322409A4 (en) | 2015-07-15 | 2019-07-24 | Aurigene Discovery Technologies Limited | SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS |
| CA2992406A1 (en) | 2015-07-15 | 2017-01-19 | Aurigene Discovery Technologies Limited | Indazole and azaindazole compounds as irak-4 inhibitors |
| HK1256242A1 (zh) * | 2015-08-04 | 2019-09-20 | Rigel Pharmaceuticals, Inc. | 吲哚化合物以及制备和使用该化合物的方法 |
| US20210292843A1 (en) | 2016-10-28 | 2021-09-23 | Children's Hospital Medical Center | Treatment of diseases associated with activated irak |
| EP4410377A3 (en) * | 2017-10-31 | 2024-11-13 | Curis, Inc. | Compounds and compositions for treating hematological disorders |
-
2018
- 2018-10-30 EP EP24168755.7A patent/EP4410377A3/en active Pending
- 2018-10-30 IL IL274248A patent/IL274248B2/en unknown
- 2018-10-30 MY MYPI2020001530A patent/MY203827A/en unknown
- 2018-10-30 CA CA3079628A patent/CA3079628A1/en active Pending
- 2018-10-30 RS RS20240586A patent/RS65572B1/sr unknown
- 2018-10-30 IL IL315025A patent/IL315025A/en unknown
- 2018-10-30 SM SM20240216T patent/SMT202400216T1/it unknown
- 2018-10-30 SG SG11202002386WA patent/SG11202002386WA/en unknown
- 2018-10-30 HR HRP20240700TT patent/HRP20240700T1/hr unknown
- 2018-10-30 KR KR1020207013352A patent/KR102697663B1/ko active Active
- 2018-10-30 HU HUE18873778A patent/HUE067356T2/hu unknown
- 2018-10-30 KR KR1020247027492A patent/KR20240130818A/ko active Pending
- 2018-10-30 LT LTEPPCT/US2018/058194T patent/LT3704108T/lt unknown
- 2018-10-30 IL IL308364A patent/IL308364B2/en unknown
- 2018-10-30 BR BR112020008214-7A patent/BR112020008214A2/pt not_active Application Discontinuation
- 2018-10-30 CN CN202311020285.0A patent/CN117064897A/zh active Pending
- 2018-10-30 EA EA202090497A patent/EA202090497A1/ru unknown
- 2018-10-30 CN CN201880066904.0A patent/CN111225911B/zh active Active
- 2018-10-30 PT PT188737787T patent/PT3704108T/pt unknown
- 2018-10-30 ES ES18873778T patent/ES2979273T3/es active Active
- 2018-10-30 AU AU2018359248A patent/AU2018359248B2/en active Active
- 2018-10-30 EP EP18873778.7A patent/EP3704108B1/en active Active
- 2018-10-30 FI FIEP18873778.7T patent/FI3704108T3/fi active
- 2018-10-30 PL PL18873778.7T patent/PL3704108T3/pl unknown
- 2018-10-30 SI SI201831106T patent/SI3704108T1/sl unknown
- 2018-10-30 DK DK18873778.7T patent/DK3704108T3/da active
- 2018-10-30 MX MX2020003666A patent/MX2020003666A/es unknown
- 2018-10-30 JP JP2020523028A patent/JP7241747B2/ja active Active
- 2018-10-30 WO PCT/US2018/058194 patent/WO2019089580A1/en not_active Ceased
- 2018-10-31 US US16/176,940 patent/US10758518B2/en active Active
-
2020
- 2020-04-21 PH PH12020550457A patent/PH12020550457A1/en unknown
- 2020-07-13 MX MX2023010882A patent/MX2023010882A/es unknown
- 2020-07-21 US US16/934,724 patent/US20200345704A1/en not_active Abandoned
-
2021
- 2021-12-30 US US17/566,371 patent/US20220370422A1/en not_active Abandoned
-
2023
- 2023-03-07 JP JP2023034551A patent/JP7476380B2/ja active Active
- 2023-08-30 AU AU2023222890A patent/AU2023222890B2/en active Active
-
2024
- 2024-04-17 JP JP2024066487A patent/JP2024096919A/ja not_active Withdrawn
-
2025
- 2025-01-22 ZA ZA2025/00725A patent/ZA202500725B/en unknown
- 2025-07-10 AU AU2025205341A patent/AU2025205341A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9598400B2 (en) | Substituted quinoline compounds and methods of use | |
| JP6342393B2 (ja) | 置換型ピラゾロン化合物及び使用方法 | |
| JP2020512343A5 (enExample) | ||
| JP7476380B2 (ja) | 血液学的障害を治療するための化合物および組成物 | |
| JP2024532374A (ja) | Ｔｅａｄ阻害剤を含む医薬品組み合わせ物及び癌の治療のためのその使用 | |
| JP2019518741A5 (enExample) | ||
| US8975282B2 (en) | Substituted pyrazolone compounds and methods of use | |
| AU2012223639A1 (en) | Substituted quinoline compounds and methods of use | |
| CA2984259A1 (en) | Combinations of inhibitors of irak4 with inhibitors of btk | |
| MX2010012290A (es) | Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer. | |
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| JP2016516791A5 (enExample) | ||
| EA034872B1 (ru) | Комбинация ингибитора mek кобиметиниба и ингибитора erk (s)-1-(1-(4-хлор-3-фторфенил)-2-гидроксиэтил)-4-(2-((1-метил-1h-пиразол-5-ил)амино)пиримидин-4-ил)пиридин-2(1h)-она для применения в лечении раковых заболеваний | |
| JP2024516353A5 (enExample) | ||
| TN2012000110A1 (en) | N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer | |
| RU2015103151A (ru) | Усилитель противоопухолевого эффекта, содержащий имидазооксазиновое соединение | |
| JP2022501434A (ja) | 血液癌を治療するための併用療法 | |
| AU2006258033A1 (en) | Synergistic modulation of FLT3 kinase using aminopyrimidines kinase modulators and a farnesyl transferase inhibitor | |
| JP2009537606A5 (enExample) | ||
| JP2018516982A5 (ja) | 免疫療法用組み合わせ組成物 | |
| WO2013177092A1 (en) | Substituted alkynyl pyridine compounds and methods of use | |
| RU2008127264A (ru) | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза | |
| TH2001002089A (th) | สารประกอบ และองค์ประกอบสำหรับการรักษาความผิดปกติทางโลหิตวิทยา | |
| NZ762393B2 (en) | Compounds and compositions for treating hematological disorders | |
| EA051654B1 (ru) | Соединения и композиции для лечения гематологических нарушений |